

Status: Closed.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcements 328, 432, and 461, and 641, as announced in Guidance and Consideration in Planning Application for Fiscal Year 1997.

Contact Person for More Information: James E. Barrow, Division of Adult and Community Health, NCCDPHP, CDC, 4770 Buford Highway, NE, M/S K30, Chamblee, Georgia 30345. Telephone 770/488-5269.

Name: Disease, Disability, and Injury Prevention and Control SEP: Cooperative Agreements for Prevention Research Centers/ National Center for Chronic Disease Prevention and Health Promotion—General Special Interest Projects, Panel Number 5, Program Announcements 328, 432, 461, and 641.

Time and Date: 1 p.m.–5 p.m., July 11, 1997.

Place: National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), CDC, 4770 Buford Highway, NE, Atlanta, Georgia 30345.

Status: Closed.

Matters to Be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcements 328, 432, 461, and 641, as announced in Guidance and Consideration in Planning Application for Fiscal Year 1997.

Contact Person for More Information: Jim Holt, Division of Adult and Community Health, NCCDPHP, CDC, 4770 Buford Highway, NE, M/S K30, Chamblee, Georgia 30341-3724. Telephone 770/488-5595.

These meetings will be closed to the public in accordance with provisions set forth in section 552b (c)(4) and (6), Title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Pub. L. 92-463.

Dated: June 10, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97-15677 Filed 6-13-97; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Request for Nominations for Members on Public Advisory Committees; Veterinary Medicine Advisory Committee

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is requesting

nominations for members to serve on the Veterinary Medicine Advisory Committee (the committee) in FDA's Center for Veterinary Medicine.

FDA has a special interest in ensuring that women, minority groups, and individuals with disabilities are adequately represented on advisory committees and, therefore, the agency encourages nominations of appropriately qualified candidates from these groups.

DATES: No cutoff date is established for receipt of nominations.

ADDRESSES: All nominations for membership should be sent to Jacquelyn L. Pace (address below).

FOR FURTHER INFORMATION CONTACT: Jacquelyn L. Pace, Center for Veterinary Medicine (HFV-200), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-5920.

SUPPLEMENTARY INFORMATION: FDA is requesting nominations for members to serve on the committee. The function of the committee is to review and evaluate available data concerning safety and effectiveness of marketed and investigational new animal drugs, feeds, and devices for use in the treatment and prevention of animal disease and increased animal production.

Criteria for Members

Persons nominated for membership on the committee shall have adequately diversified experience that is appropriate to the work of the committee in such fields as companion animal medicine, food animal medicine, avian medicine, microbiology, biometrics, toxicology, pathology, pharmacology, animal science, epidemiology and chemistry.

The specialized training and experience necessary to qualify the nominee as experts suitable for appointment are subject to review, but may include experience in medical practice, teaching, and/or research relevant to the field of activity of the committee. The term of office is 4 years.

Nomination Procedures

Any interested person may nominate one or more qualified persons for membership on the committee. Nominations shall state that the nominee is aware of the nomination, is willing to serve as a member of the committee, and appears to have no conflict of interest that would preclude committee membership. A current copy of nominee's curriculum vitae should be included. Potential candidates will be asked by FDA to provide detailed information concerning such matters as employment, financial holdings,

consultancies, and research grants or contracts in order to permit evaluation of possible sources of conflict of interest.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14 relating to advisory committees.

Dated: June 9, 1997.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 97-15636 Filed 6-13-97; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97D-0214]

Draft Guidance for Industry on Pharmacokinetics and Pharmacodynamics in Patients with Impaired Renal Function: Study Design, Data Analysis, and Impact on Dosing and Labeling; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a draft guidance entitled "Pharmacokinetics and Pharmacodynamics in Patients with Impaired Renal Function: Study Design, Data Analysis, and Impact on Dosing and Labeling." The draft guidance is intended for sponsors planning to conduct studies to assess the influence of renal impairment on the pharmacokinetics and pharmacodynamics of an investigational drug.

DATES: Written comments may be submitted on the draft guidance by August 15, 1997. General comments on the agency guidance documents are welcome at any time.

ADDRESSES: Submit written requests for single copies of "Pharmacokinetics and Pharmacodynamics in Patients with Impaired Renal Function: Study Design, Data Analysis, and Impact on Dosing and Labeling" to the Drug Information Branch (HFD-210), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. Send one self-addressed adhesive label to assist that office in processing your requests. Submit written comments on the guidance to the Dockets Management Branch (HFA-305), Food and Drug